BRPI0721651A2 - Composição farmacêutica - Google Patents

Composição farmacêutica

Info

Publication number: BRPI0721651A2
Authority: BR; Brazil
Prior art keywords: pharmaceutical composition; pharmaceutical; composition
Prior art date: 2007-05-03

Application number

BRPI0721651-3A2A

Other languages

English (en)

Inventor

Shivakumar G Kapsi

Francis X Muller

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-05-03

Filing date

2007-08-01

Publication date

2014-04-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39343460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0721651(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-08-01 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2014-04-01 Publication of BRPI0721651A2 publication Critical patent/BRPI0721651A2/pt

2017-09-19 Publication of BRPI0721651A8 publication Critical patent/BRPI0721651A8/pt

2019-10-29 Publication of BRPI0721651B1 publication Critical patent/BRPI0721651B1/pt

2021-05-25 Publication of BRPI0721651B8 publication Critical patent/BRPI0721651B8/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BRPI0721651A 2007-05-03 2007-08-01 comprimido farmacêutico e usos deste na fabricação de um medicamento para tratamento de trombocitopenia e para agonizar o receptor tpo BRPI0721651B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US91576107P	2007-05-03	2007-05-03
US94773107P	2007-07-03	2007-07-03
PCT/US2007/074918 WO2008136843A1 (en)	2007-05-03	2007-08-01	Novel pharmaceutical composition

Publications (4)

Publication Number	Publication Date
BRPI0721651A2 true BRPI0721651A2 (pt)	2014-04-01
BRPI0721651A8 BRPI0721651A8 (pt)	2017-09-19
BRPI0721651B1 BRPI0721651B1 (pt)	2019-10-29
BRPI0721651B8 BRPI0721651B8 (pt)	2021-05-25

Family

ID=39343460

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0721651A BRPI0721651B8 (pt)	2007-05-03	2007-08-01	comprimido farmacêutico e usos deste na fabricação de um medicamento para tratamento de trombocitopenia e para agonizar o receptor tpo

Country Status (35)

Country	Link
US (15)	US20100129352A1 (pt)
EP (5)	EP4400104A3 (pt)
JP (10)	JP5419866B2 (pt)
KR (3)	KR101537200B1 (pt)
CN (3)	CN101686930A (pt)
AR (1)	AR059656A1 (pt)
AU (1)	AU2007352608C1 (pt)
BR (1)	BRPI0721651B8 (pt)
CA (1)	CA2685831C (pt)
CL (1)	CL2007002242A1 (pt)
CO (1)	CO6260058A2 (pt)
CR (1)	CR11143A (pt)
CY (1)	CY1117284T1 (pt)
DK (3)	DK4218732T3 (pt)
DO (1)	DOP2009000253A (pt)
EA (2)	EA020883B1 (pt)
EC (1)	ECSP077628A (pt)
ES (3)	ES2981985T3 (pt)
FI (2)	FI4218732T3 (pt)
HR (3)	HRP20240595T3 (pt)
HU (2)	HUE067736T2 (pt)
IL (3)	IL238840B2 (pt)
JO (1)	JO3643B1 (pt)
LT (2)	LT4218732T (pt)
MA (1)	MA30236B1 (pt)
MX (1)	MX2009011881A (pt)
MY (1)	MY158072A (pt)
NZ (1)	NZ580888A (pt)
PE (3)	PE20121407A1 (pt)
PL (2)	PL2152237T3 (pt)
PT (3)	PT2152237E (pt)
SI (2)	SI2152237T1 (pt)
TW (2)	TWI439267B (pt)
WO (1)	WO2008136843A1 (pt)
ZA (1)	ZA200907710B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ECSP077628A (es)	2007-05-03	2008-12-30	Smithkline Beechman Corp	Nueva composición farmacéutica
WO2010045310A1 (en) *	2008-10-16	2010-04-22	Glaxosmithkline Llc	Method of treating thrombocytopenia
WO2010114943A1 (en)	2009-04-01	2010-10-07	Pliva Hrvatska D.O.O.	Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof
EP2434894B1 (en)	2009-05-29	2016-08-31	Novartis AG	Methods of administration of thrombopoietin agonist compounds
TWI505828B (zh)	2010-12-20	2015-11-01	葛蘭素史克智慧財產（第二）有限公司	新穎醫藥組成物
WO2012121958A2 (en) *	2011-03-08	2012-09-13	Glaxosmithkline Llc	Combination
EP2925728A4 (en) *	2012-11-27	2016-11-02	Glaxosmithkline Llc	COMBINATION
WO2015029074A2 (en) *	2013-09-02	2015-03-05	Hetero Research Foundation	Compositions of eltrombopag
KR101545268B1 (ko)	2015-02-05	2015-08-20	보령제약 주식회사	정제 및 이의 제조방법
WO2016126012A1 (en) *	2015-02-05	2016-08-11	Boryung Pharmaceutical Co., Ltd	Tablet and method of preparing the same
WO2017042839A1 (en)	2015-09-08	2017-03-16	Actavis Group Ptc Ehf.	Novel eltrombopag salt and preparation thereof
MX2018008342A (es) *	2016-01-22	2019-01-31	Jiangsu Hengrui Medicine Co	Composicion farmaceutica que comprende un derivado azoico de pirazolona biciclo-sustituido o una sal del mismo y metodo de preparacion de los mismos.
CN106361719A (zh) *	2016-08-25	2017-02-01	浙江万晟药业有限公司	一种艾曲泊帕液体胶囊及其制备方法
CN107913411B (zh) *	2016-10-11	2023-08-25	广东东阳光药业股份有限公司	艾曲泊帕包合物及其制剂和制备方法
WO2018078644A1 (en) *	2016-10-24	2018-05-03	Hetero Labs Limited	Orally disintegrating tablets of eltrombopag
GB201700621D0 (en)	2017-01-13	2017-03-01	Guest Ryan Dominic	Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
US20180280861A1 (en) *	2017-03-30	2018-10-04	JMAC Resources, Inc.	Mixer Truck Water Spray Bar
EP3395331B1 (en)	2017-04-26	2019-08-21	Alfred E. Tiefenbacher (GmbH & Co. KG)	Pharmaceutical tablet composition comprising eltrombopag olamine
CN107468662A (zh) *	2017-10-10	2017-12-15	甘宜玲	一种治疗消化不良的药物片剂及其制备方法
CN107898784B (zh) *	2017-11-01	2020-09-18	天津国际生物医药联合研究院	艾曲波帕乙醇胺在抗结核分枝杆菌感染中的应用
CN109893503A (zh) *	2017-12-11	2019-06-18	武汉武药科技有限公司	一种艾曲泊帕口服混悬液及其制备方法
EP3409272B1 (en)	2018-03-07	2020-06-24	Alfred E. Tiefenbacher (GmbH & Co. KG)	Pharmaceutical composition comprising eltrombopag olamine, reducing sugar, and polymeric binder
WO2020055364A2 (en)	2018-08-02	2020-03-19	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	A pharmaceutical composition comprising eltrombopag olamine
CN110327330A (zh) *	2019-08-08	2019-10-15	上海中医药大学	艾曲波帕在制备抗癌血管生成药物及抗癌药物组合物中的应用
US20210169854A1 (en)	2019-09-20	2021-06-10	Novartis Ag	3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation
TR201917244A1 (tr)	2019-11-07	2021-05-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Eltrombopag olami̇n i̇çeren kapsül
EP4069203A1 (en)	2019-12-06	2022-10-12	Synthon B.V.	Pharmaceutical composition comprising eltrombopag bis(monoethanolamine)
US20230022228A1 (en) *	2019-12-06	2023-01-26	Synthon B.V.	Pharmaceutical composition comprising eltrombopag bis(monoethanolamine)
EP4077641A1 (en)	2019-12-20	2022-10-26	Instil Bio (Uk) Limited	Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
WO2022056346A1 (en) *	2020-09-14	2022-03-17	Actavis Laboratories Fl, Inc.	Eltrombopag choline dosage forms
TR202014694A1 (tr) *	2020-09-16	2022-03-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Eltrombopag olami̇n i̇çeren bi̇r kati oral farmasöri̇k formülasyon
EP4014970A1 (en)	2020-12-21	2022-06-22	Genepharm S.A.	A solid oral composition of eltrombopag olamine
WO2022195545A1 (en)	2021-03-18	2022-09-22	Novartis Ag	Novel pharmaceutical formulations
WO2022201087A1 (en)	2021-03-25	2022-09-29	Novartis Ag	3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation
WO2023111187A1 (en)	2021-12-15	2023-06-22	Galenicum Health, S.L.U	Pharmaceutical compositions comprising eltrombopag
CN115919789A (zh) *	2022-12-08	2023-04-07	山东新时代药业有限公司	一种艾曲泊帕乙醇胺片及其制备方法

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE193350C (pt)
US851444A (en) *	1905-11-13	1907-04-23	Agfa Ag	Amido-oxy-sulfonic acid of phenylnaphthimidazol and process of making same.
GB779880A (en)	1953-02-27	1957-07-24	Ciba Ltd	Functional derivatives of azo-dyestuffs containing sulphonic acid groups and processfor making them
US2809963A (en) *	1954-10-26	1957-10-15	Ciba Ltd	Azo-dyestuffs
DE1046220B (de)	1956-04-21	1958-12-11	Bayer Ag	Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen
GB826207A (en)	1956-07-23	1959-12-31	Bayer Ag	ú´-ú´-dihydroxy-monoazo dyestuffs containing pyrrolidonyl residues and their metal complex compounds
US2950273A (en) *	1956-11-20	1960-08-23	Agfa Ag	Process for the production of symmetrical and unsymmetrical azo compounds
US3366619A (en) *	1965-04-09	1968-01-30	Interchem Corp	Disazo pyrazolone pigments
US4435417A (en) *	1981-02-20	1984-03-06	Gruppo Lepetit S.P.A.	Antiinflammatory 3H-naphtho[1,2-d]imidazoles
ES523609A0 (es) *	1982-07-05	1985-03-01	Erba Farmitalia	Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos.
FR2559483B1 (fr) *	1984-02-10	1986-12-05	Sandoz Sa	Composes heterocycliques contenant des groupes basiques et/ou cationiques, leur preparation et leur utilisation comme colorants
US4582831A (en) *	1984-11-16	1986-04-15	Pfizer Inc.	Anti-inflammatory polymorphic monoethanolamine salt of N-(2-pyridyl)-2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide compound, composition, and method of use therefor
FI91869C (fi) *	1987-03-18	1994-08-25	Tanabe Seiyaku Co	Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US4880788A (en) *	1987-10-30	1989-11-14	Baylor College Of Medicine	Method for preventing and treating thrombosis
CA2044951C (en) *	1990-06-21	1996-01-16	Shinya Takenaka	Automatic gain control circuit
WO1993017681A1 (en)	1992-03-02	1993-09-16	Abbott Laboratories	Angiotensin ii receptor antagonists
JPH069382A (ja)	1992-04-17	1994-01-18	Takeda Chem Ind Ltd	安定化された固型製剤およびその製造方法
US5214813A (en) *	1992-05-29	1993-06-01	Gastle Thomas H	Patient support device
US5238442A (en) *	1992-06-26	1993-08-24	Townsend Engineering Company	Method and means for applying liquid to the interior of a casing on a sausage encasing machine
US5358941A (en)	1992-12-02	1994-10-25	Merck & Co., Inc.	Dry mix formulation for bisphosphonic acids with lactose
IL109570A0 (en)	1993-05-17	1994-08-26	Fujisawa Pharmaceutical Co	Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
EP0638617A1 (de)	1993-08-13	1995-02-15	Ciba-Geigy Ag	Pigmentsalze
EP0854052B1 (en) *	1993-12-28	2000-03-22	Dai Nippon Printing Co., Ltd.	Thermal-transfer recording sheet using a specific dye
US5482546A (en) *	1994-03-30	1996-01-09	Canon Kabushiki Kaisha	Dye, ink containing the same, and ink-jet recording method and instrument using the ink
US5760038A (en) *	1995-02-06	1998-06-02	Bristol-Myers Squibb Company	Substituted biphenyl sulfonamide endothelin antagonists
US5746821A (en) *	1995-02-13	1998-05-05	Engelhard Corporation	Pigment compositions
KR100436680B1 (ko)	1995-06-07	2004-09-18	글락소 그룹 리미티드	트롬보포이에틴 수용체에 결합하는 펩티드 및 화합물
US5622818A (en) *	1995-11-29	1997-04-22	Eastman Kodak Company	Color photographic elements containing yellow colored magenta dye forming masking couplers
US5669967A (en) *	1996-05-30	1997-09-23	Engelhard Corporation	Pigment compositions
US5932546A (en) *	1996-10-04	1999-08-03	Glaxo Wellcome Inc.	Peptides and compounds that bind to the thrombopoietin receptor
PE71699A1 (es)	1997-02-07	1999-08-03	Sepracor Inc	Composicion farmaceutica de descarboetoxiloratadina sin lactosa, no higroscopica y anhidra
SE9701398D0 (sv)	1997-04-15	1997-04-15	Astra Pharma Prod	Novel compounds
GB9715830D0 (en)	1997-07-25	1997-10-01	Basf Ag	Reactive dyes containing piperazine
AU9265698A (en)	1997-09-02	1999-03-22	Boehringer Mannheim Gmbh	Mpl-receptor ligands, process for their preparation, medicaments containing themand their use for the treatment and prevention of thrombocytopaenia and anaemia
GB9718913D0 (en)	1997-09-05	1997-11-12	Glaxo Group Ltd	Substituted oxindole derivatives
US6280959B1 (en) *	1997-10-31	2001-08-28	Smithkline Beecham Corporation	Metal complexes
DE19851389A1 (de)	1998-11-07	2000-05-11	Dystar Textilfarben Gmbh & Co	Gelbe Farbstoffmischungen von wasserlöslichen faserreaktiven Azofarbstoffen und ihre Verwendung
GC0000177A (en)	1998-12-17	2006-03-29	Smithkline Beecham	Thrombopoietin mimetics
CO5210907A1 (es)	1999-05-12	2002-10-30	Novartis Ag	Solvatos de pometrozina, insecticidamente activos, composiciones que contienen estos compuestos y metodos tanto para producir dichos compuestos y composiciones como para controlar plagas animales con estas composiciones
CN1376150A (zh)	1999-07-26	2002-10-23	盐野义制药株式会社	具有血栓形成素受体拮抗作用的药物组合物
EP1213965B1 (en)	1999-09-10	2006-01-18	Smithkline Beecham Corporation	Thrombopoietin mimetics
AU771460B2 (en)	1999-09-24	2004-03-25	Smithkline Beecham Corporation	Thrombopoietin mimetics
WO2001034585A1 (en)	1999-11-05	2001-05-17	Smithkline Beecham Corporation	Semicarbazone derivatives and their use as thrombopoietin mimetics
ES2160560T1 (es)	1999-11-10	2001-11-16	Curacyte Ag	Colorantes o,o'-dihidroxi-azoicos como constituyentes de medicamentos para el tratamiento de trombopenias.
WO2001047498A2 (en) *	1999-12-23	2001-07-05	Pfizer Products Inc.	Hydrogel-driven layered drug dosage form comprising sertraline
TWI284639B (en)	2000-01-24	2007-08-01	Shionogi & Co	A compound having thrombopoietin receptor agonistic effect
HUP0001417A2 (hu)	2000-04-07	2002-12-28	Sanofi-Synthelabo	Gyógyászatilag alkalmazható új sók, eljárás előállításukra és azokat tartalmazó gyógyászati készítmények
US6436915B1 (en) *	2000-04-07	2002-08-20	Kinetek Pharmaceuticals, Inc.	Pyrazole compounds
US6214813B1 (en)	2000-04-07	2001-04-10	Kinetek Pharmaceuticals, Inc.	Pyrazole compounds
US6428871B1 (en) *	2000-05-05	2002-08-06	Michael Cozzolino	Method of manufacturing decorative wood products from engineered wood products
CY2010012I2 (el)	2000-05-25	2020-05-29	Novartis Ag	Μιμητικα θρομβοποιητινης
EP1349613A4 (en)	2000-12-19	2005-09-21	Smithkline Beecham Corp	THROMBOPOIETINMIMETIKA
JP2004532614A (ja)	2000-12-21	2004-10-28	スミスクライン・ビーチャム・コーポレイション	金属キレート化アゴニストによる細胞膜受容体の活性化の調節
WO2002059099A1 (fr)	2001-01-26	2002-08-01	Shionogi & Co., Ltd.	Composes cycliques presentant un agonisme envers le recepteur de thrombopoietine
KR20040025891A (ko) *	2001-01-26	2004-03-26	시오노기세이야쿠가부시키가이샤	트롬보포이에틴 수용체 효현작용을 갖는 할로겐 화합물
EP1370252A4 (en)	2001-03-01	2006-04-05	Smithkline Beecham Corp	Thrombopoietin mimetics
JP3927001B2 (ja)	2001-06-15	2007-06-06	三菱化学株式会社	色素セット、インクセット並びに記録方法
AR033485A1 (es)	2001-09-25	2003-12-26	Otsuka Pharma Co Ltd	Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
AU2002333114B2 (en)	2001-11-30	2008-09-04	Qlt Inc.	Hydrazonopyrazole derivatives and their use as therapeutics
AU2003213673A1 (en)	2002-03-01	2003-09-16	Pintex Pharmaceuticals, Inc.	Pin1-modulating compounds and methods of use thereof
LT2630954T (lt) *	2002-03-20	2017-01-25	Civitas Therapeutics, Inc.	Levodopos įvedimas į plaučius
AUPS245302A0 (en)	2002-05-21	2002-06-13	Cuskelly, John	Ventilation control device
TWI280128B (en)	2002-05-22	2007-05-01	Smithkline Beecham Corp	3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
JP4562523B2 (ja)	2002-06-06	2010-10-13	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	トロンボポエチン疑似体
AU2003297925A1 (en)	2002-12-13	2004-07-09	Smithkline Beecham Corporation	Thrombopoietin mimetics
US20090143453A1 (en) *	2003-04-29	2009-06-04	Connie Erickson-Miller	Methods for treating degenerative diseases/injuries
US20090298179A1 (en) *	2003-04-29	2009-12-03	Connie Erickson-Miller	Methods For Treating Degenerative Diseases/Injuries
US20090048318A1 (en) *	2003-04-29	2009-02-19	Connie Erickson-Miller	Methods for treating degenerative diseases/injuries
EP1622609A4 (en)	2003-04-29	2008-09-03	Smithkline Beecham Corp	METHODS OF TREATING DEGENERATIVE DISEASES / LESIONS
TW200526638A (en)	2003-10-22	2005-08-16	Smithkline Beecham Corp	2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
EP2436379A1 (en) *	2004-11-17	2012-04-04	BioMarin Pharmaceutical Inc.	Stable tablet formulation
EP1942906A2 (en) *	2005-10-13	2008-07-16	SmithKline Beecham Corporation	Methods for the preservation of platelet efficacy during storage
JP4226002B2 (ja)	2005-12-27	2009-02-18	ルビコン株式会社	積層形フィルムコンデンサの製造方法
US20080055395A1 (en)	2006-08-29	2008-03-06	Motorola, Inc.	Creating a dynamic group call through similarity between images
UY30915A1 (es)	2007-02-16	2008-09-02	Smithkline Beecham Corp	Método de tratamiento de canceres
ECSP077628A (es) *	2007-05-03	2008-12-30	Smithkline Beechman Corp	Nueva composición farmacéutica
GB0719235D0 (en)	2007-10-02	2007-11-14	Glaxo Group Ltd	Novel compounds

2007
- 2007-07-27 EC EC2007007628A patent/ECSP077628A/es unknown
- 2007-07-31 PE PE2012000401A patent/PE20121407A1/es not_active Application Discontinuation
- 2007-07-31 PE PE2007000990A patent/PE20080773A1/es active IP Right Grant
- 2007-07-31 PE PE2015002111A patent/PE20151953A1/es unknown
- 2007-08-01 FI FIEP23166852.6T patent/FI4218732T3/fi active
- 2007-08-01 EA EA200971018A patent/EA020883B1/ru active Protection Beyond IP Right Term
- 2007-08-01 ES ES15199469T patent/ES2981985T3/es active Active
- 2007-08-01 ES ES23166852T patent/ES3032244T3/es active Active
- 2007-08-01 HR HRP20240595TT patent/HRP20240595T3/hr unknown
- 2007-08-01 TW TW096128135A patent/TWI439267B/zh active
- 2007-08-01 CL CL200702242A patent/CL2007002242A1/es unknown
- 2007-08-01 PT PT78406329T patent/PT2152237E/pt unknown
- 2007-08-01 CA CA2685831A patent/CA2685831C/en active Active
- 2007-08-01 LT LTEP23166852.6T patent/LT4218732T/lt unknown
- 2007-08-01 PT PT231668526T patent/PT4218732T/pt unknown
- 2007-08-01 MX MX2009011881A patent/MX2009011881A/es active IP Right Grant
- 2007-08-01 LT LTEP15199469.6T patent/LT3090730T/lt unknown
- 2007-08-01 DK DK23166852.6T patent/DK4218732T3/da active
- 2007-08-01 AU AU2007352608A patent/AU2007352608C1/en active Active
- 2007-08-01 AR ARP070103395A patent/AR059656A1/es not_active Application Discontinuation
- 2007-08-01 HR HRP20250383TT patent/HRP20250383T3/hr unknown
- 2007-08-01 EP EP24178734.0A patent/EP4400104A3/en active Pending
- 2007-08-01 ES ES07840632.9T patent/ES2565179T3/es active Active
- 2007-08-01 PL PL07840632T patent/PL2152237T3/pl unknown
- 2007-08-01 MY MYPI20094618A patent/MY158072A/en unknown
- 2007-08-01 PT PT151994696T patent/PT3090730T/pt unknown
- 2007-08-01 CN CN200780053601A patent/CN101686930A/zh active Pending
- 2007-08-01 NZ NZ580888A patent/NZ580888A/en unknown
- 2007-08-01 DK DK07840632.9T patent/DK2152237T3/en active
- 2007-08-01 CN CN2012101813537A patent/CN102688207A/zh active Pending
- 2007-08-01 HR HRP20160206TT patent/HRP20160206T1/hr unknown
- 2007-08-01 KR KR1020147008579A patent/KR101537200B1/ko active Active
- 2007-08-01 PL PL15199469.6T patent/PL3090730T3/pl unknown
- 2007-08-01 JO JOP/2007/0314A patent/JO3643B1/ar active
- 2007-08-01 JP JP2010507380A patent/JP5419866B2/ja active Active
- 2007-08-01 US US12/598,673 patent/US20100129352A1/en not_active Abandoned
- 2007-08-01 FI FIEP15199469.6T patent/FI3090730T3/fi active
- 2007-08-01 SI SI200731753T patent/SI2152237T1/sl unknown
- 2007-08-01 HU HUE15199469A patent/HUE067736T2/hu unknown
- 2007-08-01 IL IL238840A patent/IL238840B2/en unknown
- 2007-08-01 HU HUE07840632A patent/HUE027209T2/en unknown
- 2007-08-01 KR KR1020097025142A patent/KR101475971B1/ko active Active
- 2007-08-01 MA MA30120A patent/MA30236B1/fr unknown
- 2007-08-01 KR KR1020157000147A patent/KR101632851B1/ko active Active
- 2007-08-01 CN CN2012101823191A patent/CN102697745A/zh active Pending
- 2007-08-01 EP EP23166852.6A patent/EP4218732B1/en active Active
- 2007-08-01 IL IL274602A patent/IL274602B2/en unknown
- 2007-08-01 SI SI200732203T patent/SI3090730T1/sl unknown
- 2007-08-01 TW TW102139693A patent/TWI538674B/zh active
- 2007-08-01 EP EP23166857.5A patent/EP4218733A1/en not_active Ceased
- 2007-08-01 DK DK15199469.6T patent/DK3090730T3/da active
- 2007-08-01 EP EP15199469.6A patent/EP3090730B9/en active Active
- 2007-08-01 BR BRPI0721651A patent/BRPI0721651B8/pt active IP Right Grant
- 2007-08-01 EP EP07840632.9A patent/EP2152237B1/en not_active Revoked
- 2007-08-01 EA EA201400387A patent/EA034294B1/ru not_active IP Right Cessation
- 2007-08-01 WO PCT/US2007/074918 patent/WO2008136843A1/en active Application Filing
2009
- 2009-10-28 US US12/607,305 patent/US8052994B2/en active Active
- 2009-10-28 US US12/607,291 patent/US8052993B2/en active Active
- 2009-10-28 US US12/607,320 patent/US8062665B2/en active Active
- 2009-10-28 US US12/607,284 patent/US8071129B2/en active Active
- 2009-10-28 US US12/607,330 patent/US8052995B2/en active Active
- 2009-10-30 DO DO2009000253A patent/DOP2009000253A/es unknown
- 2009-11-02 IL IL201891A patent/IL201891A/en active IP Right Grant
- 2009-11-03 ZA ZA2009/07710A patent/ZA200907710B/en unknown
- 2009-11-05 CO CO09125378A patent/CO6260058A2/es not_active Application Discontinuation
- 2009-12-03 CR CR11143A patent/CR11143A/es unknown
2011
- 2011-10-13 US US13/272,367 patent/US8828430B2/en active Active
2013
- 2013-10-10 JP JP2013212550A patent/JP5735078B2/ja active Active
2014
- 2014-08-04 US US14/450,569 patent/US20140341991A1/en not_active Abandoned
2015
- 2015-04-15 JP JP2015083393A patent/JP6144713B2/ja active Active
- 2015-09-11 US US14/851,497 patent/US20160031822A1/en not_active Abandoned
2016
- 2016-03-11 CY CY20161100209T patent/CY1117284T1/el unknown
- 2016-03-18 US US15/073,708 patent/US20160199353A1/en not_active Abandoned
- 2016-11-04 US US15/343,382 patent/US20170112771A1/en not_active Abandoned
2017
- 2017-04-04 JP JP2017074555A patent/JP6560289B2/ja active Active
- 2017-06-30 US US15/638,693 patent/US20170296512A1/en not_active Abandoned
- 2017-12-22 US US15/852,090 patent/US20180117009A1/en not_active Abandoned
2018
- 2018-08-03 US US16/054,451 patent/US20180338926A1/en not_active Abandoned
2019
- 2019-03-18 US US16/356,498 patent/US20190209479A1/en not_active Abandoned
- 2019-04-08 JP JP2019073452A patent/JP2019123747A/ja active Pending
2021
- 2021-03-25 JP JP2021051850A patent/JP2021100968A/ja active Pending
2022
- 2022-11-08 JP JP2022178573A patent/JP2023011888A/ja active Pending
2024
- 2024-11-11 JP JP2024196745A patent/JP7642148B2/ja active Active
- 2024-11-11 JP JP2024196746A patent/JP7642149B2/ja active Active
2025
- 2025-02-25 JP JP2025027513A patent/JP2025081605A/ja active Pending

Also Published As

Publication number	Publication date
HRP20240595T3 (hr)	2024-09-13
US8828430B2 (en)	2014-09-09
EP3090730B1 (en)	2024-04-10
JP2015129195A (ja)	2015-07-16
NZ580888A (en)	2012-03-30
TWI538674B (zh)	2016-06-21
FI4218732T3 (fi)	2025-07-04
PE20151953A1 (es)	2016-01-14
US20100047348A1 (en)	2010-02-25
JP2025020368A (ja)	2025-02-12
ZA200907710B (en)	2014-03-26
FI3090730T3 (fi)	2024-05-20
JP2023011888A (ja)	2023-01-24
TW200843742A (en)	2008-11-16
IL238840B (en)	2020-05-31
JP5419866B2 (ja)	2014-02-19
CN102688207A (zh)	2012-09-26
JP2010526140A (ja)	2010-07-29
EP2152237A1 (en)	2010-02-17
EP2152237A4 (en)	2012-02-08
US20100047347A1 (en)	2010-02-25
IL274602B2 (en)	2024-12-01
EA200971018A1 (ru)	2010-04-30
US20170296512A1 (en)	2017-10-19
JP2025020367A (ja)	2025-02-12
EA034294B1 (ru)	2020-01-27
AU2007352608A1 (en)	2008-11-13
US20160199353A1 (en)	2016-07-14
ECSP077628A (es)	2008-12-30
CR11143A (es)	2010-03-22
JP5735078B2 (ja)	2015-06-17
HUE027209T2 (en)	2016-10-28
EP4218732B1 (en)	2025-03-26
DK4218732T3 (da)	2025-06-16
US8052995B2 (en)	2011-11-08
CO6260058A2 (es)	2011-03-22
EP3090730B9 (en)	2024-07-03
KR20150008513A (ko)	2015-01-22
JP6560289B2 (ja)	2019-08-14
SI2152237T1 (sl)	2016-04-29
IL238840B2 (en)	2024-11-01
US8071129B2 (en)	2011-12-06
HUE067736T2 (hu)	2024-11-28
IL274602B (en)	2021-10-31
PL3090730T3 (pl)	2024-08-26
US20180117009A1 (en)	2018-05-03
HRP20160206T1 (hr)	2016-04-08
TW201410240A (zh)	2014-03-16
KR101632851B1 (ko)	2016-06-22
KR20140049086A (ko)	2014-04-24
ES2981985T3 (es)	2024-10-14
ES2565179T3 (es)	2016-04-01
US20190209479A1 (en)	2019-07-11
EP4218732A1 (en)	2023-08-02
DK2152237T3 (en)	2016-03-14
EP4400104A3 (en)	2024-10-09
EP3090730A1 (en)	2016-11-09
JO3643B1 (ar)	2020-08-27
US20180338926A1 (en)	2018-11-29
JP2019123747A (ja)	2019-07-25
EA201400387A1 (ru)	2014-07-30
BRPI0721651A8 (pt)	2017-09-19
PE20080773A1 (es)	2008-08-23
JP7642149B2 (ja)	2025-03-07
JP2017137343A (ja)	2017-08-10
CA2685831A1 (en)	2008-11-13
ES3032244T3 (en)	2025-07-16
BRPI0721651B1 (pt)	2019-10-29
JP2014005302A (ja)	2014-01-16
IL201891A (en)	2016-02-29
MX2009011881A (es)	2009-12-16
WO2008136843A1 (en)	2008-11-13
JP7642148B2 (ja)	2025-03-07
BRPI0721651B8 (pt)	2021-05-25
US20100040684A1 (en)	2010-02-18
EP2152237B1 (en)	2015-12-30
AR059656A1 (es)	2008-04-23
KR101475971B1 (ko)	2014-12-23
IL274602A (en)	2020-06-30
LT4218732T (lt)	2025-06-25
LT3090730T (lt)	2024-06-25
JP2025081605A (ja)	2025-05-27
US8062665B2 (en)	2011-11-22
JP2021100968A (ja)	2021-07-08
AU2007352608B2 (en)	2011-12-08
IL238840A0 (en)	2015-06-30
AU2007352608C1 (en)	2024-11-21
US20170112771A1 (en)	2017-04-27
PE20121407A1 (es)	2012-11-15
US20100040683A1 (en)	2010-02-18
KR20100020456A (ko)	2010-02-22
CN101686930A (zh)	2010-03-31
DOP2009000253A (es)	2009-12-15
EA020883B1 (ru)	2015-02-27
JP6144713B2 (ja)	2017-06-07
EP4218733A1 (en)	2023-08-02
TWI439267B (zh)	2014-06-01
US20100129352A1 (en)	2010-05-27
PT3090730T (pt)	2024-06-06
US20120093927A1 (en)	2012-04-19
SI3090730T1 (sl)	2024-07-31
HK1136968A1 (en)	2010-07-16
EP4400104A2 (en)	2024-07-17
DK3090730T3 (da)	2024-07-15
CN102697745A (zh)	2012-10-03
MY158072A (en)	2016-08-30
US20160031822A1 (en)	2016-02-04
US20140341991A1 (en)	2014-11-20
PT4218732T (pt)	2025-06-11
US20100047346A1 (en)	2010-02-25
CA2685831C (en)	2013-11-26
CY1117284T1 (el)	2017-04-26
US8052993B2 (en)	2011-11-08
CL2007002242A1 (es)	2008-02-08
HRP20250383T3 (hr)	2025-07-18
PL2152237T3 (pl)	2016-06-30
IL201891A0 (en)	2010-06-16
US8052994B2 (en)	2011-11-08
PT2152237E (pt)	2016-03-28
KR101537200B1 (ko)	2015-07-15
MA30236B1 (fr)	2009-03-02

Publication	Publication Date	Title
LTC2140867I2 (lt)	2018-11-12	Farmacinė kompozicija
LTPA2018014I1 (lt)	2018-12-10	Farmacinė kompozicija 514
BRPI0721651A2 (pt)	2014-04-01	Composição farmacêutica
BRPI0715712A2 (pt)	2014-06-24	Composição farmacêutica
RU2493831C3 (ru)	2017-06-08	Фармацевтические композиции
BRPI0719393A2 (pt)	2015-03-31	Composição farmacêutica
DK2120884T3 (da)	2011-02-07	Farmaceutisk sammensætning
BRPI0820381A2 (pt)	2015-05-19	Formulações farmacêuticas
EP2191826A4 (en)	2010-09-15	PHARMACEUTICAL COMPOSITION
BRPI0813775A2 (pt)	2015-01-06	Composição
ATE528048T1 (de)	2011-10-15	Schweisshemmende/desodorierende zusammensetzung
BRPI0716445A2 (pt)	2013-09-17	composiÇço farmacÊutica
BRPI0720234A2 (pt)	2013-12-24	Composição farmacêutica
DK2285413T3 (da)	2012-08-27	Farmaceutisk sammensætning
DK2966175T3 (da)	2019-07-01	Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
PT2209464E (pt)	2014-09-05	Composição farmacêutica antimalárica
BRPI0810557A2 (pt)	2016-07-19	composição
EP2236149A4 (en)	2012-12-26	MEDICAL COMPOSITION
BRPI0811274A2 (pt)	2014-10-07	Composição
BRPI0921313A2 (pt)	2015-12-29	composição farmaucêutica
EP2197828A4 (en)	2011-09-21	FULLERENE MULTI-ADDUCT COMPOSITIONS
BRPI0820198A2 (pt)	2019-09-24	composições farmacêuticas
BRPI0811002A2 (pt)	2015-01-27	Composição biofertilizante
BRPI0820960A2 (pt)	2017-05-09	composição
BRPI0912171A2 (pt)	2017-10-31	composição farmacêutica

Legal Events

Date	Code	Title	Description
2017-02-21	B25D	Requested change of name of applicant approved	Owner name: GLAXOSMITHKLINE LLC (US)
2017-08-22	B25A	Requested transfer of rights approved	Owner name: GLAXO GROUP LIMITED (GB)
2017-09-05	B25A	Requested transfer of rights approved	Owner name: NOVARTIS PHARMA AG (CH)
2017-09-19	B25A	Requested transfer of rights approved	Owner name: NOVARTIS AG (CH)
2018-01-16	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-24	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-01-02	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-05-07	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2019-08-27	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2019-10-29	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/10/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/10/2019, OBSERVADAS AS CONDICOES LEGAIS
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/08/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF